Suppr超能文献

美国医疗机构提供数字健康技术治疗阿片类药物使用障碍。

Provision of Digital Health Technologies for Opioid Use Disorder Treatment by US Health Care Organizations.

机构信息

Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Lebanon, New Hampshire.

出版信息

JAMA Netw Open. 2023 Jul 3;6(7):e2323741. doi: 10.1001/jamanetworkopen.2023.23741.

Abstract

IMPORTANCE

Digital health technologies may expand organizational capacity to treat opioid use disorder (OUD). However, it remains unclear whether these technologies serve as substitutes for or complements to traditional substance use disorder (SUD) treatment resources in health care organizations.

OBJECTIVE

To characterize the use of patient-facing digital health technologies for OUD by US organizations with accountable care organization (ACO) contracts.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study analyzed responses to the 2022 National Survey of Accountable Care Organizations (NSACO), collected between October 1, 2021, and June 30, 2022, from US organizations with Medicare and Medicaid ACO contracts. Data analysis was performed between December 15, 2022, and January 6, 2023.

EXPOSURES

Treatment resources for SUD (eg, an addiction medicine specialist, sufficient staff to treat SUD, medications for OUD, a specialty SUD treatment facility, a registry to identify patients with OUD, or a registry to track mental health for patients with OUD) and organizational characteristics (eg, organization type, Medicaid ACO contract).

MAIN OUTCOMES AND MEASURES

The main outcomes included survey-reported use of 3 categories of digital health technologies for OUD: remote mental health therapy and tracking, virtual peer recovery support programs, and digital recovery support for adjuvant cognitive behavior therapy (CBT). Statistical analysis was conducted using descriptive statistics and multivariable logistic regression models.

RESULTS

Overall, 276 of 505 organizations responded to the NSACO (54.7% response rate), with a total of 304 respondents. Of these, 161 (53.1%) were from a hospital or health system, 74 (24.2%) were from a physician- or medical group-led organization, and 23 (7.8%) were from a safety-net organization. One-third of respondents (101 [33.5%]) reported that their organization used at least 1 of the 3 digital health technology categories, including remote mental health therapy and tracking (80 [26.5%]), virtual peer recovery support programs (46 [15.1%]), and digital recovery support for adjuvant CBT (27 [9.0%]). In an adjusted analysis, organizations with an addiction medicine specialist (average marginal effect [SE], 32.3 [4.7] percentage points; P < .001) or a registry to track mental health (average marginal effect [SE], 27.2 [3.8] percentage points; P < .001) were more likely to use at least 1 category of technology compared with otherwise similar organizations lacking these capabilities.

CONCLUSIONS AND RELEVANCE

In this cross-sectional study of 276 organizations with ACO contracts, organizations used patient-facing digital health technologies for OUD as complements to available SUD treatment capabilities rather than as substitutes for unavailable resources. Future studies should examine implementation facilitators to realize the potential of emerging technologies to support organizations facing health care practitioner shortages and other barriers to OUD treatment delivery.

摘要

重要性

数字健康技术可能会扩大医疗机构治疗阿片类药物使用障碍(OUD)的组织能力。然而,目前尚不清楚这些技术在医疗机构中是替代还是补充传统的物质使用障碍(SUD)治疗资源。

目的

描述具有问责制医疗组织(ACO)合同的美国组织对患者使用数字健康技术治疗 OUD 的情况。

设计、地点和参与者:这是一项横断面研究,分析了 2022 年全国问责制医疗组织调查(NSACO)的应答情况,应答是在 2021 年 10 月 1 日至 2022 年 6 月 30 日之间,从具有医疗保险和医疗补助 ACO 合同的美国组织中收集的。数据分析于 2022 年 12 月 15 日至 2023 年 1 月 6 日进行。

暴露情况

物质使用障碍的治疗资源(例如,成瘾医学专家、治疗 SUD 的足够工作人员、OUD 的药物、专门的 SUD 治疗设施、识别 OUD 患者的登记处或跟踪 OUD 患者心理健康的登记处)和组织特征(例如,组织类型、医疗补助 ACO 合同)。

主要结果和措施

主要结果包括调查报告的 3 类用于 OUD 的数字健康技术的使用情况:远程心理健康治疗和跟踪、虚拟同伴康复支持计划以及辅助认知行为疗法(CBT)的数字康复支持。使用描述性统计和多变量逻辑回归模型进行统计分析。

结果

共有 505 个组织中的 276 个(54.7%的应答率)对 NSACO 做出了回应,共有 304 名应答者。其中,161 名(53.1%)来自医院或医疗系统,74 名(24.2%)来自医生或医疗集团领导的组织,23 名(7.8%)来自保障网组织。三分之一的应答者(101 [33.5%])报告其组织使用了至少 1 种数字健康技术类别,包括远程心理健康治疗和跟踪(80 [26.5%])、虚拟同伴康复支持计划(46 [15.1%])和辅助 CBT 的数字康复支持(27 [9.0%])。在调整后的分析中,与不具备这些能力的类似组织相比,具有成瘾医学专家(平均边际效应[SE],32.3 [4.7]个百分点;P <.001)或用于跟踪心理健康的登记处(平均边际效应[SE],27.2 [3.8]个百分点;P <.001)的组织更有可能使用至少 1 种技术类别。

结论和相关性

在这项对具有 ACO 合同的 276 个组织的横断面研究中,组织使用了面向患者的数字健康技术来治疗 OUD,这些技术是对现有 SUD 治疗能力的补充,而不是对无法获得的资源的替代。未来的研究应研究实施促进因素,以实现新兴技术的潜力,这些技术可以支持面临医疗保健从业者短缺和 OUD 治疗提供其他障碍的组织。

相似文献

1
Provision of Digital Health Technologies for Opioid Use Disorder Treatment by US Health Care Organizations.
JAMA Netw Open. 2023 Jul 3;6(7):e2323741. doi: 10.1001/jamanetworkopen.2023.23741.
2
Expanding Inpatient Addiction Consult Services Through Accountable Care Organizations for Medicaid Enrollees: A Modeling Study.
J Addict Med. 2022;16(5):570-576. doi: 10.1097/ADM.0000000000000972. Epub 2022 Feb 8.
4
Implementation of collaborative care for depressive disorder treatment among accountable care organizations.
Medicine (Baltimore). 2021 Jul 9;100(27):e26539. doi: 10.1097/MD.0000000000026539.
5
Determinants of success in Shared Savings Programs: An analysis of ACO and market characteristics.
Healthc (Amst). 2017 Mar;5(1-2):53-61. doi: 10.1016/j.hjdsi.2016.08.002. Epub 2016 Sep 28.
6
Optimization of Medication Use at Accountable Care Organizations.
J Manag Care Spec Pharm. 2017 Oct;23(10):1054-1064. doi: 10.18553/jmcp.2017.23.10.1054.
7
All-payer value-based contracting in organizations with Medicare ACOs.
Am J Manag Care. 2023 Nov;29(11):601-604. doi: 10.37765/ajmc.2023.89456.
9
Availability of Medication for Opioid Use Disorder Among Accountable Care Organizations: Evidence From a National Survey.
Psychiatr Serv. 2024 Feb 1;75(2):182-185. doi: 10.1176/appi.ps.20230087. Epub 2023 Aug 24.
10
Innovations in Care Delivery for Patients With Serious Mental Illness Among Accountable Care Organizations.
Psychiatr Serv. 2022 Aug 1;73(8):889-896. doi: 10.1176/appi.ps.202000484. Epub 2022 Apr 5.

引用本文的文献

3
Characteristics of accountable care organizations offering methadone to patients with opioid use disorder.
Health Aff Sch. 2025 Apr 9;3(4):qxaf074. doi: 10.1093/haschl/qxaf074. eCollection 2025 Apr.
4
Formative evaluation of the implementation of digital therapeutics for opioids and other substance use disorders in primary care (DIGITS trial).
Implement Res Pract. 2024 Dec 12;5:26334895241301670. doi: 10.1177/26334895241301670. eCollection 2024 Jan-Dec.
5
Behavioral health treatment delivery by social workers in accountable care organizations.
Soc Work Health Care. 2024;63(8-10):600-622. doi: 10.1080/00981389.2024.2427750. Epub 2024 Nov 22.
6
Digital Health Readiness: Making Digital Health Care More Inclusive.
JMIR Mhealth Uhealth. 2024 Oct 9;12:e58035. doi: 10.2196/58035.
7
Evaluating generative AI responses to real-world drug-related questions.
Psychiatry Res. 2024 Sep;339:116058. doi: 10.1016/j.psychres.2024.116058. Epub 2024 Jun 26.
8
Feasibility and acceptability of a novel digital therapeutic combining behavioral and pharmacological treatment for opioid use disorder.
Digit Health. 2024 May 29;10:20552076241258400. doi: 10.1177/20552076241258400. eCollection 2024 Jan-Dec.
9
Closing the Digital Divide in Interventions for Substance Use Disorder.
J Psychiatr Brain Sci. 2024;9(1). doi: 10.20900/jpbs.20240002. Epub 2024 Mar 26.
10
Digital Phenotyping for Mood Disorders: Methodology-Oriented Pilot Feasibility Study.
J Med Internet Res. 2023 Dec 29;25:e47006. doi: 10.2196/47006.

本文引用的文献

1
An overview of and recommendations for more accessible digital mental health services.
Nat Rev Psychol. 2022 Feb;1(2):87-100. doi: 10.1038/s44159-021-00003-1. Epub 2022 Jan 26.
2
Many Clinicians Implement Digital Equity Strategies To Treat Opioid Use Disorder.
Health Aff (Millwood). 2023 Feb;42(2):182-186. doi: 10.1377/hlthaff.2022.00803.
3
Smartphone app engagement and clinical outcomes in a hybrid clinic.
Psychiatry Res. 2023 Jan;319:115015. doi: 10.1016/j.psychres.2022.115015. Epub 2022 Dec 18.
4
Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the US.
JAMA Psychiatry. 2023 Jan 1;80(1):93-95. doi: 10.1001/jamapsychiatry.2022.3673.
5
Emerging approaches to redressing multi-level racism and reproductive health disparities.
NPJ Digit Med. 2022 Nov 4;5(1):169. doi: 10.1038/s41746-022-00718-2.
6
Understanding users' perspectives on mobile apps for anxiety management.
Front Digit Health. 2022 Sep 1;4:854263. doi: 10.3389/fdgth.2022.854263. eCollection 2022.
7
A framework for digital health equity.
NPJ Digit Med. 2022 Aug 18;5(1):119. doi: 10.1038/s41746-022-00663-0.
9
Scale-up of Digital Innovations in Health Care: Expert Commentary on Enablers and Barriers.
J Med Internet Res. 2022 Mar 11;24(3):e24582. doi: 10.2196/24582.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验